Objective To analyze the changes of levels of serum soluble growth stimulation expressed gene 2 (sST2) and albumin (ALB) in patients with chronic heart failure (CHF) and their correlation with prognosis. Methods The data of 216 patients with CHF (CHF group) and 98 healthy subjects with physical examination (healthy control group) were retrospectively analyzed. The changes in levels of serum sST2 and ALB between both groups and among different grades of New York Heart Association (NYHA), and their correlation with NYHA grading and cardiac function and their diagnostic value on the prognosis in patients with CHF were compared. Results The level of serum sST2 and LVEF value of CHF group were significantly higher than those of healthy control group (P<0.05) while the level of serum ALB was significantly lower than that of healthy control group (P<0.05). There were significant differences in the levels of serum sST2 and ALB and LVEF value among patients with different HYHA grades and pairwise comparison between the any two grades (P<0.05). Serum sST2 level in patients with CHF was positively correlated with NYHA grading (P<0.001) and was negatively correlated with LVEF (P<0.001), and serum ALB level was negatively correlated with NYHA grading (P<0.001), and was positively correlated with LVEF (P<0.001). Serum sST2 level of poor prognosis group was significantly higher than that of good prognosis group (P<0.05) while serum ALB level was significantly lower than that of good prognosis group (P<0.05). ROC curve analysis of serum sST2 combined with ALB in diagnosing poor prognosis in CHF patients showed that the AUC and sensitivity were 0.907 and 98.04%, which were higher than the single diagnosis, and the specificity was 81.82%, which was lower than the single diagnosis. Conclusion The levels of serum sST2 and ALB in patients with CHF are correlated with NYHA grading and cardiac function, and the combination of the two indicators has high diagnostic value on predicting the poor prognosis of patients.

Oral squamous cell carcinoma (OSCC) is a common head and neck malignancy. Approximately 50% to 60% of patients with OSCC are diagnosed at a locally advanced stage (clinical staging III-IVa). Even with comprehensive and sequential treatment primarily based on surgery, the 5-year overall survival rate remains below 50%, and patients often suffer from postoperative functional impairments such as difficulties with speaking and swallowing. Programmed death receptor-1 (PD-1) inhibitors are increasingly used in the neoadjuvant treatment of locally advanced OSCC and have shown encouraging efficacy. However, clinical practice still faces key challenges, including the definition of indications, optimization of combination regimens, and standards for efficacy evaluation. Based on the latest research advances worldwide and the clinical experience of the expert group, this expert consensus systematically evaluates the application of PD-1 inhibitors in the neoadjuvant treatment of locally advanced OSCC, covering combination strategies, treatment cycles and surgical timing, efficacy assessment, use of biomarkers, management of special populations and immune related adverse events, principles for immunotherapy rechallenge, and function preservation strategies. After multiple rounds of panel discussion and through anonymous voting using the Delphi method, the following consensus statements have been formulated: 1) Neoadjuvant therapy with PD-1 inhibitors can be used preoperatively in patients with locally advanced OSCC. The preferred regimen is a PD-1 inhibitor combined with platinum based chemotherapy, administered for 2-3 cycles. 2) During the efficacy evaluation of neoadjuvant therapy, radiographic assessment should follow the dual criteria of Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune RECIST (iRECIST). After surgery, systematic pathological evaluation of both the primary lesion and regional lymph nodes is required. For combination chemotherapy regimens, PD-L1 expression and combined positive score need not be used as mandatory inclusion or exclusion criteria. 3) For special populations such as the elderly (≥ 70 years), individuals with stable HIV viral load, and carriers of chronic HBV/HCV, PD-1 inhibitors may be used cautiously under the guidance of a multidisciplinary team (MDT), with close monitoring for adverse events. 4) For patients with a poor response to neoadjuvant therapy, continuation of the original treatment regimen is not recommended; the subsequent treatment plan should be adjusted promptly after MDT assessment. Organ transplant recipients and patients with active autoimmune diseases are not recommended to receive neoadjuvant PD-1 inhibitor therapy due to the high risk of immune related activation. Rechallenge is generally not advised for patients who have experienced high risk immune related adverse events such as immune mediated myocarditis, neurotoxicity, or pneumonitis. 5) For patients with a good pathological response, individualized de escalation surgery and function preservation strategies can be explored. This consensus aims to promote the standardized, safe, and precise application of neoadjuvant PD-1 inhibitor strategies in the management of locally advanced OSCC patients.

Objective: To explore the relationship between serum homocysteine (Hcy), interleukin-5 (IL-5), folate and core symptoms in children with autism spectrum disorders, so as to provide potential biomarkers for early diagnosis and intervention of diseases. Methods: A total of 106 children with autism spectrum disorders and 106 healthy children with matched sex and age in Lu an People s Hospital were enrolled as autism group and healthy group between May 2020 to December 2023. On the day of admission, levels of serum Hcy, IL-5 and folate were detected. The core symptoms in autism group were evaluated by Autism Behavior Checklist (ABC), Wechsler Preschool and Primary Scale of Intelligence-fourth edition(WPPSI-IV), Childhood Autism Rating Scale (CARS) and Social Responsiveness Scale (SRS). The levels of serum Hcy, IL-5 and folate in the two groups were compared by t- test. The relationship between serum Hcy, IL-5, folate and core symptoms in children with autism spectrum disorders was determined by Pearson correlation analysis. Results: The levels of serum Hcy and IL-5 in autism group were (7.48±0.32) μmol/L and (345.77±32.51) pg/mL, higher than those in healthy group [(6.11±0.54) μmol/L, (274.04±25.17) pg/mL], while folate level was lower than that in healthy group [(15.24±3.47) ng/mL, (22.51±4.69) ng/mL], the differences were statistically significant ( t =22.47, 17.96, 12.83, all P < 0.05 ). In autism group, levels of serum Hcy and IL-5 were positively correlated with scores of ABC, CARS and SRS ( r =0.29, 0.53 , 0.54; 0.45, 0.41, 0.50), while negatively correlated with WPPSI-IV score ( r =-0.28, -0.26)(all P <0.05). The folate level was negatively correlated with scores of ABC, CARS and SRS ( r =-0.55, -0.40, -0.25), while positively correlated with WPPSI-IV score ( r =0.41) (all P <0.05). Conclusion Children with ASD show elevated serum Hcy and IL-5 alongside decreased folate,and three markers correlate with core symptoms and intellectual level.

Background: Small studies suggest that variations in plasma potassium (p-K) levels may affect cardiac contractile function. A substudy to the recently published POTCAST trial demonstrated short-term improvements in myocardial function in patients randomized to potassium-increasing treatment. However, the long-term effects of increasing p-K on cardiac function remain unclear. This study aimed to investigate whether treatment that increases p-K improves diastolic and systolic myocardial function as assessed by echocardiography during long-term follow-up in a Danish implantable cardioverter-defibrillator (ICD) cohort. Methods: The POTCAST trial randomized patients with an ICD (1:1) to either usual therapy (control group) or treatment with oral potassium supplements and/or mineralocorticoid receptor antagonists (high-normal potassium group). In this substudy, consecutive patients from both arms of the POTCAST trial were included. Echocardiography was performed at baseline and repeated after > 6 months for the current study to compare changes in left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), global constructive work (GCW), and diastolic parameters (E, e’, and E/e’) between the high-normal potassium and control groups. Results: A total of 289 patients (mean age, 58 ± 13.4 years; 77.5% male) were included in the study. The median follow-up time between baseline and follow-up echocardiography was 729 days (interquartile range, 511–986 days).From baseline to follow-up the high-normal potassium group had an increase in mean difference in p-K of 0.22 mmol/L (95% confidence interval [CI], –0.31 to –0.13; P < 0.001) compared to the control group. In the high-normal potassium group e’lat increased by 0.77 cm/sec (95% CI, 0.12–1.40; P = 0.020), and E/e’lat decreased by –1.15 (95% CI, –2.1 to –0.25; P = 0.013) on average compared to the control group. No significant differences were observed in changes in other diastolic parameters. For systolic function, no significant differences were found between groups in terms of change in LVEF (–0.6%; 95% CI, –2.17 to 1.02; P = 0.475), GLS (–0.26%; 95% CI, –0.8 to 0.4; P = 0.472), or GCW (–3.99 mmHg; 95% CI, –89.5 to 81.6; P = 0.927). Conclusions In contrast to previous short-term findings, when myocardial function was assessed by echocardiography, long-term potassium-increasing treatment led to only minor improvements in diastolic function in a contemporary Danish ICD cohort.

We report a case of a female farmer from the Yichang suburb, aged 68 years, who had been suffering from the infection for 3 years and had a history of seeking medical treatment at a community hospital and receiving blood transfusions. Her hemoglobin was as low as 28 g/L during this visit, and she had been ill for a long time with severe anemia. Routine stool examination revealed hookworm eggs. After active treatment, the patient recovered and was discharged from the hospital.

Objective To conduct a comparative analysis of the epidemic characteristics of hemorrhagic fever with renal syndrome (HFRS) in Northeast and Southwest China from 2005 to 2020, and to provide a reference for developing regional prevention and control strategies. Methods Descriptive epidemiological methods were used to analyze the epidemiological characteristics of HFRS outbreaks. The Joinpoint regression model was employed to calculate the annual percentage change (APC) and average annual percentage change (AAPC), thereby analyzing the trends in HFRS incidence. Results From 2005 to 2020, 63 878 HFRS cases were reported in Northeast China (average annual incidence: 3.58/100,000), showing a significant downward trend (AAPC=-13.08%, P<0.05). In Southwest China, 5 313 cases were reported (average annual incidence: 0.168/100 000) with stable overall incidence (AAPC=2.73%, P>0.05) but obvious inter-provincial differences. Northeast had a primary autumn-winter peak (Nov-Dec) and a secondary spring-summer peak (Apr-Jun), while Southwest showed the opposite seasonal pattern. For population distribution, both regions had males (Northeast: 45.01/100 000; Southwest: 1.76/100 000) and farmers aged 20-60 as the main high-risk groups, but differed in the second largest group: household workers/unemployed in the Northeast and students in the Southwest. Incidence presented an inverted ^”U^”-shape with age, peaking in the 40-50 years group. Geographically, high-incidence areas were widely distributed across multiple prefectures (e.g., Shuangyashan) in the Northeast, while in the Southwest, the distribution was highly concentrated, clustered only in a few ethnic minority autonomous prefectures such as Dali and Chuxiong in Yunnan. Conclusion The incidence of HFRS in Northeast China continues to decline, while it remains generally stable but shows localized increases in Southwest China, exhibiting regional differences in seasonal characteristics and geographical distribution. The differences in epidemic patterns across different regions may be related to climate and host species. Differentiated prevention and control strategies should be developed based on the specific epidemic characteristics of each region.

Patients with lung cancer experience a heavy symptom burden during the perioperative period, which seriously affects their recovery and quality of life. Traditional symptom management models rely mainly on scheduled ward rounds during hospitalization and outpatient follow-up after discharge. However, they have limitations such as delayed symptom recognition, lack of post-discharge monitoring, and non-quantitative symptom assessment, which often lead to delayed interventions and low patient satisfaction. In recent years, the symptom management model based on electronic patient-reported outcomes (ePRO) has been increasingly valued in clinical practice. Existing high-level evidence from both domestic and international studies indicates that, through proactive monitoring, real-time alerts, and remote interventions, this model enables dynamic and continuous symptom management and helps improve patient recovery and healthcare experience. As a supplement to routine medical care, the ePRO-based symptom management model aims to enhance the quality of care rather than replace existing medical processes. To promote the standardized application of this model in perioperative lung cancer care, this consensus integrates domestic and international evidence. After multiple rounds of voting by more than 50 experts, it formulates 12 consensus statements covering the three core components, symptom monitoring, alerting, and intervention, to provide scientific and practical recommendations for clinical practice.

Objective To construct three models, SARIMA, XGBoost, and LightGBM, to predict the future trend of human brucellosis in mainland China, and to provide a basis for formulating policies for the prevention and control of brucellosis. Methods Monthly case data of human brucellosis in mainland China from 2014 to 2023 were collected. The SARIMA model was constructed using R 4.4.1. The XGBoost and LightGBM models were constructed using Python 3.8. Results From 2014 to 2023, a total of 536,443 cases of human brucellosis were reported in mainland China. The incidence rate first decreased and then increased. The average annual incidence was 3.82 per 100,000 people. The LightGBM model effectively captured the complex time‑series characteristics of human brucellosis. It had good performance while accurately predicting the trend. Based on the optimal LightGBM model, a short‑term prediction was made for the trend of human brucellosis in 2024. The results showed that in 2024, the disease would still have a clear seasonal pattern in China. The peak months were from April to June. The highest number of cases was in June (8,733.48 cases). The lowest number was in October (3,260.69 cases). The predicted total number of cases for the year was about 70,260. Overall, the incidence remained high. Conclusion China remains in a high-incidence phase of human brucellosis, necessitating further implementation of prevention and control measures and enhanced supervision and monitoring in key regions.

BACKGROUND Acute pancreatitis (AP) is a heterogeneous inflammatory disease, and its risk and severity may be shaped more by body fat distribution than by overall obesity. However, the shared genetic basis between AP and depot-specific fat accumulation remains unclear. METHODS We meta-analyzed AP genome-wide association study (GWAS) summary statistics from FinnGen, the Million Veteran Program, and the UK Biobank, including 18,045 cases and 1,285,319 controls. Four magnetic resonance imaging (MRI)-derived fat distribution traits, namely intrapancreatic fat deposition (IPFD), liver fat (LF), visceral adipose tissue (VAT), and abdominal subcutaneous adipose tissue (ASAT), were examined. We estimated genetic correlations using linkage disequilibrium score regression (LDSC) and high definition likelihood (HDL); identified pleiotropic loci using cross-phenotype association analysis (CPASSOC) and functional mapping and annotation (FUMA); tested colocalization; and assessed gene-level, pathway, and cell-type signals using multi-marker analysis of genomic annotation (MAGMA), Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG), and web-based cell-type-specific enrichment analysis (WebCSEA). Two-sample and multivariable Mendelian randomization (MR) analyses were conducted to evaluate causal associations. RESULTS The AP meta-analysis identified nine loci of genome-wide significance, including four previously unreported regions. AP showed positive genetic correlations with all four fat traits, particularly with VAT and ASAT. CPASSOC identified 50 pleiotropic risk loci across 26 independent regions, with recurrent signals at 2p21, 5q32, 7q34, and 16q23.1. MAGMA prioritized 63 unique pleiotropic genes, including ABCG5/ABCG8, SPINK1, PRSS1, CTRB1, TM4SF4, and ZFYVE21. Enrichment analyses highlighted digestion; lipid metabolism; xenobiotic processing; inflammation; and pancreatic, intestinal, and hepatic cell contexts. MR supported independent effects of IPFD and VAT on AP risk. CONCLUSION This multilevel genome-wide analysis provides evidence of the shared genetic architecture between AP and depot-specific fat distribution and highlights the pancreas-intestine-liver regulatory axis as a relevant biological context.

Objective To explore the relationship between ambulatory blood pressure changes and health-related behaviors as well as sleep quality in hypertensive patients. Methods A retrospective study was conducted on 684 patients who underwent 24-hour ambulatory blood pressure monitoring at Chengdu Fifth People's Hospital between January 2023 and April 2025. The cohort included 502 hypertensive patients and 182 non-hypertensive patients. Clinical data from both groups of patients were collected. Their health-related behaviors and sleep quality were investigated. Pearson correlation analysis was conducted to explore the relationship between ambulatory blood pressure changes and health-related behaviors as well as sleep quality in hypertensive patients. Results The differences in dSBP, dDBP, nSBP, nDBP, 24-hour SBP, 24-hour DBP, 24-hour SBP CV, and 24-hour DBP CV levels between the two groups were statistically significant (P<0.05). The scores of the Active Health Behavior Scale (AHBS) in the hypertension group were lower than those in the non-hypertension group, while the scores of the Pittsburgh Sleep Quality Index (PSQI) in the hypertension group were higher than those in the non-hypertension group (P<0.05). AHBS showed a negative correlation with dSBP, dDBP, nSBP, nDBP, 24 h SBP, 24 h DBP, 24 h SBP CV, and 24 h DBP CV (P<0.05), while PSQI showed a positive correlation with dSBP, dDBP, nSBP, nDBP, 24 h SBP, 24 h DBP, 24 h SBP CV, and 24 h DBP CV (P<0.05). Conclusion Health-related behaviors and sleep quality can influence ambulatory blood pressure through various mechanisms, including neural, endocrine, and vascular functions.